Cubist made $1B bid for Optimer last year; Bayer snaps up private German drugmaker Steigerwald;

@FiercePharma: AstraZeneca advances three cancer drugs into late-stage trials. Story | Follow @FiercePharma

 @EricPFierce: Pfizer to give privileges to small group of contract manufacturers as it makes network more efficient. Article | Follow @EricPFierce

> Cubist Pharmaceuticals ($CBST) had offered $20 per share, or nearly $1 billion for Optimer Pharmaceuticals ($OPTR) even before the latter put itself up for sale earlier this year, Reuters reports. Report

> Bayer snapped up a privately held German drug company, Steigerwald, that posted about $79 million in sales last year. Report

> An FDA warning about the risks of anemia drugs for kidney patients inspired dialysis centers to step back a bit on their use, but for-profit centers still gave their patients more of the drugs than not-for-profits did, a study finds. Report

> A "flash fire" at an Amgen ($AMGN) facility in South San Francisco, CA, injured a man who was collecting hazardous waste. Report

> Sir Michael Rawlins, former chief of the U.K. cost-effectiveness agency until his March retirement, has joined the board of a New York-based biotech, raising concerns about a potential conflict of interest. Report (sub. req.)

Medical Device News

@FierceMedDev: New special report: After tough times, hip implant revenue projected to grow again. Feature | Follow @FierceMedDev

@MarkHFierce: Roche may be selling its glucose meter business, Reuters reports--blame competition and worsening reimbursement. Story | Follow @MarkHFierce

 @DamianFierce: In case you missed it: Hospira endured another FDA warning letter, this time over the pumps it wants to keep. Article | Follow @DamianFierce

> St. Jude snags CE mark for 3-D stent imaging. News

> Boston Scientific launches stent study for pancreatic cancer surgery. Item

> Blood Dx spots knee, hip implant allergies before procedure. DxExtra

Biotech News

@FierceBiotech: In case you missed it last night: Scientists use cloning method to create embryonic stem cells. Article | Follow @FierceBiotech

@JohnCFierce: Roche's next-gen Rituxan candidate impresses in first look at PhIII data. Report | Follow @JohnCFierce

@RyanMFierce: @SanofiUS hunts for clinical trial recruits in growing social network. Article | Follow @RyanMFierce

> AstraZeneca revs up PhIII cancer plans as rivals steal ASCO spotlight. News

> Gilead speeds ahead on idelalisib with promising leukemia data. Story

> Amgen, Novartis aim to fuel biotech startups in alliance with Atlas Venture. Article

Pharma Manufacturing News

> CEO of J&J OTC unit in Korea faces criminal action over plant foul-up. News

> Recalls jump 32% in first quarter. Article

> Pfizer to close Ireland plant by next year. Story

> Pfizer to pick some contract manufacturers for new elevated role. More

Vaccines News

> Taliban drops campaign against polio vaccine. News

> Human-to-human coronavirus spread looks likely. Item

> Cash injection raises hopes of diabetes vaccine. More

> Media reports used to track global vaccine backlash. Article

> Indian rotavirus vax set to undercut GSK and Merck. Story

And Finally... Men who stayed fit in middle age were less likely to die from three common cancers than those who were out of shape, researchers found. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.